The Ongoing Study of Alzheimer's Disease

Summary of articles on ongoing Alzheimer's study Your biggest fear is that a loved one gets old. It may be that your loved one is experiencing tremendous pain and suffering, or simply fear of his or her death. Imagine now that this person shares many good memories with you Love does not know you anymore. I am worried about you a little now. Alzheimer's disease is very difficult for injured people and their families, but do not think your case is hopeless.

Existing clinical trials on turmeric and Alzheimer's disease include small studies published in 2012 on Alzheimer's disease research and treatment. In this study, 36 patients with mild to moderate Alzheimer's disease were divided into two groups. One group received curcumin treatment. During the 24 th week, members of the second group received placebo treatment during the same period. Healthy eating habits, regular exercise, weight loss, avoidance of smoking, participation in social activities, and mental health activities are essential to keep the brain healthy with age. In addition, certain natural remedies (such as omega-3 fatty acids and resveratrol) help to avoid Alzheimer's disease.

Delaying the progression of Alzheimer's disease: Several ongoing studies have shown promising results with regard to the use of cannabis and Alzheimer's disease. This study showed that THC can proliferate in the brain and ultimately can help delay the formation of harmful plaques that develop into Alzheimer's disease. As flower buds mature, it turns purple and gives it its name. Plants have a grape aroma that also helps to help give it an unforgetable name that will help it stand out more than other cannabis strains. The taste of grapes and fruits remains in the mouth and helps to eat better.

Researchers work hard to find effective drugs for Alzheimer's disease. However, so far, no studies have shown that effective herbal substitutes can improve the cognitive function of Alzheimer's disease. Recent studies have tested apple juice, but the study showed that it only improves the behavior of people with Alzheimer's disease rather than cognitive symptoms. The results of our clinical trials are very promising. It shows improvement of various elements of cognitive function in elderly patients with Alzheimer's disease who were taking Bacopa monnieri for 6 months. We noticed that we used a very coarse but simple cognitive function measurement (MMSES). However, as this is the first test to test Bacopa monnieri for Alzheimer's disease patients, we believe that it will provide valuable data for further detailed research.